The IBC plays an important role in oversight of research, and integrating IBC functions with those of IRBs and IACUCs is key to ensuring effective review, especially for translational research projects. Clear communication among these committees and with investigators is essential for an efficient program that can rapidly communicate with other regulatory groups.
This intermediate- to advanced-level program will provide information, tools, and guidance for IBC, IRB, and IACUC professionals to improve integration to best support research that is ethical, collaborative, and interdisciplinary. IBC personnel will have opportunities for benchmarking, sharing resources such as standard operating procedures, and networking with colleagues in the field.
View the agenda here: here.
E-materials Link: http://bit.ly/iacuc18ibc
*To receive the password, you must pre-register for this program. Please note that only those pre-registered for a preconference program are permitted into the room. If you would like to attend or switch your preconference program while you are on-site, please go to the PRIM&R help desk to see if there is still space in the program.
Director, Research Integrity and Compliance Review Office
Colorado State UniversityAssociate Professor, Department of Microbiology, Immunology, and Pathology
Dr. Dobos received her Ph.D. from Colorado State University, applying proteomics mass spectrometry to describe novel glycosylation of proteins from Mycobacterium tuberculosis. She continued her research at the Centers for Disease Control and Prevention (Atlanta, GA) under Drs. Fredrick Quinn and Harold King, working on infection models of Mycobacterium ulcerans and M. tuberculosis, prior to taking an appointment at the Mayo Clinic Research Center (Scottsdale, AZ) under the direction of Dr. Jamie Lee where she gained experience in NIAID sponsored contracts managing the day-to-day activities of an eosinophil research and animal modeling contract. She returned to CSU in 2002 to facilitate a tuberculosis research material and vaccine testing contract where she subsequently served as PI from 2007-2011. Dr. Dobos maintains a contract with BEI resources for the production, provision, and consultation for biological reagents derived from Mycobacterium spp and other bacterial zoonotic pathogens, and serves as a PI for a number of other projects aimed at the discovery of biomarkers and alternate vaccines for diseases caused by Mycobacterium spp. In 2014, Dr. Dobos accepted the appointment as Associate Director of the Office of Research Integrity and Compliance Review, which manages the operations of all bioethics compliance committees for the university (IACUC, IRB, IBC) as well other required research compliance activities (COI, RCR), and regulated research (QA; GxP). She subsequently became the director of this office in January of 2016. Her research experiences afford her an appreciation of the magnitude of work conducted by dedicated, credentialed staff required to facilitate ethical human, animal, and biosafety research. She is committed to supporting these team members, and working to improve relationships and efficiencies across research and administrative groups. Finally, Dr. Dobos serves as peer review subject matter expert for a number of granting agencies, and is an Editor for the journals Microbiology and Scientific Reports.
Monday, March 19
1:00 PM – 4:30 PM
Senior IBC Coordinator, Research Integrity and Compliance Review Office
Colorado State University
Christine M. Johnson, MS, RBP, is the Senior IBC Coordinator in the Research Integrity and Compliance Review Office at Colorado State University (CSU). In this capacity, she manages the CSU IBC Program, as well as the DURC Oversight Program, the Biosafety Stewardship Initiative, and the BSL3 Advisory Committee. She has been the Senior IBC Coordinator since 2006 and has seen how changing compliance regulations impact researchers, the compliance committees, and her own office. Prior to becoming the IBC Coordinator, she spent 10 years conducting laboratory research with a focus on testing therapies and studying the immune response to Leishmaniasis and Tuberculosis in various animal models. She has a Master of Science in Microbiology and extensive experience working in the BSL3. She is also the co-founder and Past-President of the Front Range Biological Safety Association.
Monday, March 19
1:00 PM – 4:30 PM
The asset you are trying to access is locked. Please enter your access key to unlock.